Related Experiment Video

Updated: May 9, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Hsp90 inhibitors in breast cancer: a systematic review

Flora Zagouri1, Theodoros N Sergentanis, Dimosthenis Chrysikos

  • 1Department of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Vas Sofias Ave & Lourou Str, Athens 11521, Greece.

Breast (Edinburgh, Scotland)
|July 23, 2013
PubMed
Abstract

Insights

Heat shock protein 90 (Hsp90) inhibitors show promise for breast cancer treatment, particularly for HER2-positive, triple-negative, and resistant types. Further research is needed as no Hsp90 inhibitors are yet approved for clinical use.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Heat shock protein 90 (Hsp90) is a crucial molecular chaperone implicated in cancer cell survival and proliferation.
  • Targeting Hsp90 offers a promising therapeutic strategy for various cancers, including breast cancer.

Purpose of the Study:

  • To systematically review and synthesize existing data on the efficacy and safety of Hsp90 inhibitors in breast cancer treatment.
  • To evaluate the potential of Hsp90 inhibitors across different breast cancer subtypes.

Main Methods:

  • Systematic review conducted following PRISMA guidelines.
  • Searched MEDLINE and ClinicalTrials.gov databases for relevant studies.
  • Included articles using terms: "breast", "cancer", "Hsp90", "inhibitors".

Main Results:

  • Nineteen articles involving 190 patients were analyzed.
  • Hsp90 inhibitors demonstrated significant clinical activity in HER2-positive metastatic breast cancer.
  • Emerging data suggest potential roles in treating triple-negative and aromatase inhibitor-resistant breast cancer.

Conclusions:

  • Hsp90 inhibitor development has advanced rapidly in the past decade.
  • No Hsp90 inhibitor has yet been approved for clinical practice.
  • Phase III trials are currently lacking for Hsp90 inhibitors in breast cancer treatment.
Keywords:
AlvespimycinBreast cancerHsp90 inhibitorsRetaspimycinTanespimycin

More Related Videos

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...